2.57
Medicus Pharma Ltd stock is traded at $2.57, with a volume of 414.05K.
It is down -3.38% in the last 24 hours and down -61.81% over the past month.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
See More
Previous Close:
$2.66
Open:
$2.73
24h Volume:
414.05K
Relative Volume:
2.08
Market Cap:
$47.00M
Revenue:
-
Net Income/Loss:
$-11.73M
P/E Ratio:
-1.8588
EPS:
-1.3826
Net Cash Flow:
$-10.37M
1W Performance:
-12.88%
1M Performance:
-61.81%
6M Performance:
-2.65%
1Y Performance:
+0.00%
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MDCX
Medicus Pharma Ltd
|
2.57 | 47.00M | 0 | -11.73M | -10.37M | -1.3826 |
![]()
LLY
Lilly Eli Co
|
791.24 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.38 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
NVO
Novo Nordisk Adr
|
74.34 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
![]()
ABBV
Abbvie Inc
|
185.48 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
116.41 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma targets horse cancer with new trial – ICYMI - Proactive financial news
Medicus Pharma to present at BIO 2025 - Proactive financial news
Medicus Pharma to Present at Bio Convention and Expand Cancer Treatment Portfolio - TipRanks
Medicus Pharma Ltd. to Present at 2025 Bio International Convention - Newsfile
BMO Launches Human Capital Factor US Equity ETF - The Globe and Mail
If I Could Only Buy and Hold a Single Stock, This Would Be It. - The Globe and Mail
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong - The Globe and Mail
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing Biotech Market - citybuzz -
Medicus Pharma submits development plan for novel Equine Cancer treatment - Proactive financial news
Medicus Pharma’s (MDCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market - openPR.com
Should You Invest $1,000 in Verizon Today? - The Globe and Mail
Medicus Pharma prices $7 million share offering - MSN
Medicus Pharma advances cancer patch for horses By Investing.com - Investing.com South Africa
Medicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horses - Proactive financial news
Is Newmont Stock Outperforming the Nasdaq? - The Globe and Mail
Medicus Pharma Submits FDA Plan for Novel Equine Cancer Treatment - TipRanks
Medicus Pharma advances cancer patch for horses - Investing.com
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses - Yahoo Finance
5 Monster Stocks to Hold for the Next 10 Years - The Globe and Mail
Certain Common Stock of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 9-JUN-2025. - marketscreener.com
Eli Lilly Stock (LLY) Gets Multiple Wall Street Downgrades - The Globe and Mail
How major US stock indexes fared Thursday, 6/5/2025 - The Globe and Mail
Why Shares of Robinhood Are Surging This Week - The Globe and Mail
The Golden Retracement Keeps Sending Wheat Lower & New Video! - The Globe and Mail
Why Wolfspeed Stock Is Soaring Today - The Globe and Mail
Multiple insider buying at BuildDirect.com (BILD) - The Globe and Mail
Are Options Traders Betting on a Big Move in Autodesk Stock? - The Globe and Mail
Medicus Pharma completes $7 million public offering By Investing.com - Investing.com South Africa
Why Broadcom Stock Blew Past the Market on Monday - The Globe and Mail
Medicus Pharma completes $7 million public offering - Investing.com
Medicus Pharma Secures $7 Million for Cancer Treatment Trials - TipRanks
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering - Newsfile
Medicus Pharma closes $7M public offering - Proactive financial news
2 Nasdaq Stocks to Buy in June - The Globe and Mail
Biotech Stocks Plummet As Public Offerings Shake Market - Finimize
Health Sector Experiences Mixed Fortunes As Trials And Stock Moves Shake Up Market - Finimize
Small cap wrap: ReconAfrica, Charbone Hydrogen, Medicus Pharma.... - Proactive financial news
Sector Update: Health Care - marketscreener.com
Form 424B4 Medicus Pharma Ltd. - StreetInsider
Medicus Pharma Prices $7 Million Public Offering; Shares Fall - marketscreener.com
Medicus Pharma unveils pricing of $7M public offering - Proactive financial news
Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen - Defense World
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials - TipRanks
Medicus Pharma Secures $7M Funding to Advance Revolutionary Skin Cancer Patch Through Phase 2 Trials - Stock Titan
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering - Newsfile
Definity Financial Corporation Announces Increased Size of Previously Announced Private Placements of Common Shares to $385 million - The Globe and Mail
Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares - marketscreener.com
Definity Financial Corporation Announces Agreement to Acquire Canadian Operations of Travelers for $3.3 billion and Concurrent $351 million Private Placements of Common Shares - The Globe and Mail
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):